E-Posters: Transplant Immunossupression
Sunday September 22, 2024 from 21:00 to 22:00
TBD
Lectures
  • P.272 Four-drug immunosuppressive treatment as rescue therapy in kidney transplant recipients with repeated episodes of acute rejection or chronic active allograft rejection
    Dr. Wanda Rojas, Argentina
  • P.530 Disseminated cryptococcosis and histoplasmosis in a renal transplant recipient
    Dr. Abhishek Suhas Borle, India
  • P.531 Serum and urine nucleic acid screening tests for BK polyomavirus-associated nephropathy in kidney and kidney-pancreas transplant recipients: Diagnostic test accuracy review Please note there have been some changes since the abstract submission - Thank you
    Dr. Thida Maung Myint, Australia
  • P.532 Advanced Kaposi Sarcoma With Extensive Pulmonary Involvement After Kidney Transplantation
    Dr. Walaa Dabbas, United States
  • P.533 A prospective randomised study from Eastern India comparing Basiliximab versus no induction immunosuppression in low immunological risk kidney transplant recipients
    Dr. Varun Gosain, India
  • P.535 One year outcome of Anti-T-Lymphocyte Globulin (ATLG) Induction Therapy in Kidney Transplantation: A Single-Center Retrospective Analysis
    Dr. Kamal Kiran Mukkavilli, India
  • P.534 Comparison of anti-human T-Lymphocyte immunoglobulin (r-ATLG - Grafalon) vs anti-thymocyte globulin (r-ATG - Thymoglobulin) in kidney transplant: A 5-year follow-up study
    Dr. Vijay Kumar Sinha, India
  • P.536 The efficacy of Anti T-Lymphocyte Globulin as Induction Therapy in Kidney Transplantation: A Single-Center Retrospective Analysis
    Dr. Piyali Sarkar, India
  • P.537 Atypical Hemolytic Uremic Syndrome: A Case Report Of 41 Year Old Female
    Dr. Piyali Sarkar, India
  • P.540 Immunosuppressant-induced changes in gut microbiota cause loss of skeletal muscle mass
    Dr. Mitsuru Tomizawa, Japan
  • P.542 Long-term clinical outcomes of late conversion to once-daily tacrolimus and sirolimus combination in stable kidney transplant recipients
    Prof. Cheol Woong Jung, Korea
  • P.547 Tolerogenic properties of CD3 immunotoxin induction therapy and progress toward clinical trials in transplantation
    Dr. Nalu Navarro-Alvarez, United States